Brain

Nature volume 609, pages 822–828 (2022)Cite this article

35k Accesses

10 Citations

205 Altmetric

Metrics details

On-target–off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates1,2. In diseases of the central nervous system, drugs with brain-restricted pharmacology are highly desirable. Here we report a strategy to achieve inhibition of mammalian target of rapamycin (mTOR) while sparing mTOR activity elsewhere through the use of the brain-permeable mTOR inhibitor RapaLink-1 and the brain-impermeable FKBP12 ligand RapaBlock. We show that this drug combination mitigates the systemic effects of mTOR inhibitors but retains the efficacy of RapaLink-1 in glioblastoma xenografts. We further present a general method to design cell-permeable, FKBP12-dependent kinase inhibitors from known drug scaffolds. These inhibitors are sensitive to deactivation by RapaBlock, enabling the brain-restricted inhibition of their respective kinase targets.

Administration of a small-molecule drug often leads to systemic pharmacological effects that contribute to both efficacy and toxicity and define its therapeutic index. Although off-target effects may be mitigated by chemical modifications that improve the specificity of the drug, on-target–off-tissue toxicity represents a unique challenge that requires precise control over tissue partitioning. On-target–off-tissue toxicities affect commonly used drugs such as statins (myopathy caused by inhibition of HMG CoA reductase in skeletal muscle)1 and first-generation antihistamines (drowsiness caused by blockade of the H1 receptor in the brain)2 and can sometimes preclude the safe usage of otherwise effective therapeutic agents. Chemical inhibitors of mTOR provide a case in point. Although both allosteric and orthosteric mTOR inhibitors have been investigated in numerous diseases of the central nervous system (CNS) including tuberous sclerosis complex3,4,5, glioblastoma6,7,8,9 and alcohol use disorder10,11,12, systemic inhibition of mTOR is associated with various dose-limiting adverse effects: immune suppression, metabolic disorders and growth inhibition in children13,14. If the pharmacological effects of these mTOR inhibitors could be confined to the CNS, their therapeutic window could be substantially widened. Here we present a chemical strategy that allows brain-specific mTOR inhibition through the combination of two pharmacological agents: a brain-permeable mTOR inhibitor (RapaLink-1) whose function requires the intracellular protein FK506-binding protein 12 (FKBP12), and a brain-impermeant ligand of FKBP12 (RapaBlock). When used in a glioblastoma xenograft model, this drug combination drove tumour regression without detectable systemic toxicity. We further demonstrate that this strategy can be adapted to achieve brain-specific inhibition of other kinase targets by developing a method to convert known kinase inhibitors into FKBP12-dependent formats.

Therapeutic targeting of mTOR kinase can be achieved both allosterically and orthosterically. The first-generation mTOR inhibitors rapamycin and its analogues (rapalogues) bind to the FK506 rapamycin-binding (FRB) domain of mTOR as a complex with the intracellular protein FKBP12, resulting in substrate-dependent allosteric inhibition of mTOR complex 1 (refs. 15,16,17). Second-generation mTOR kinase inhibitors (TORKi) directly bind in the ATP pocket of mTOR and inhibit the activity of both mTOR complex 1 and complex 2 (refs. 18,19,20). The third-generation mTOR inhibitor RapaLink-1 is a bitopic ligand that simultaneously engages the ATP pocket and an allosteric pocket (the FRB domain) of mTOR, achieving potent and durable inhibition of its kinase activity21. Despite its large molecular weight (1,784 Da), RapaLink-1 is cell and brain permeant and has shown enhanced in vivo efficacy in driving glioblastoma regression compared with earlier mTOR inhibitors7.

Because RapaLink-1 contains a TOR kinase inhibitor (TORKi) moiety (Fig. 1a, grey shading) that binds in the ATP pocket, we wondered whether the interaction of RapaLink-1 with FKBP12 is essential for its inhibition of mTOR. We performed in vitro kinase assays with purified mTOR protein and found that RapaLink-1 exhibited identical half-maximal inhibitory concentration (IC50) values as MLN0128 (the TORKi portion of RapaLink-1) whether FKBP12 was present (Fig. 1b), indicating that RapaLink-1 can engage the active site of mTOR independent of FKBP12 in a cell-free setting. However, when we tested RapaLink-1 in cells, we observed a strong dependency on FKBP12 for mTOR inhibition. In K562 cells expressing dCas9-KRAB, CRISPRi-mediated knockdown of the gene encoding FKBP12 with two distinct single guide RNAs (sgRNAs) drastically impeded its cellular activity (Fig. 1c). This effect was even more pronounced when we used FK506 (a high-affinity natural ligand of FKBP12) to pharmacologically block the ligand-binding site of FKBP12. Similar FKBP12 dependence of RapaLink-1 was observed when we monitored mTOR signalling by western blot (Fig. 1d; see also ref. 21). Whereas 10 nM RapaLink-1 reduced phospho-S6 (S240/244) and phospho-4EBP (T37/46) to almost undetectable levels, the combination of 10 nM RapaLink-1 and 10 µM FK506 showed no effect on either marker.

a, Chemical structures of RapaLink-1 and FK506. b, Inhibition of mTOR activity by MLN128, RapaLink-1 or rapamycin in the presence or absence of 10 µM FKBP12 in the in vitro kinase assay (n = 2; data are plotted as individual points). c, K562 CRISPRi cells transduced with sgRNAs targeting GAL4-4 (control) or FKBP12 were treated with RapaLink-1 and cell proliferation was assessed after 72 h. In the last listed condition, cells were transduced with sgRNA but treated with RapaLink-1 in the presence of 10 µM FK506 (n = 3). Data are presented as mean ± s.d. d, Immunoblot analysis of mTOR signalling in MCF7 cells treated with DMSO, RapaLink-1, FK506 or a combination of RapaLink-1 and FK506. Results shown are representative of three independent experiments. Actin was the loading control. For gel source data, see Supplementary Fig. 1. MW, molecular weight. e, Schematics of the proposed working model. The grey circles indicate cellular membranes.

Source data

These results highlight that although FKBP12 is not essential for RapaLink-1 to bind to and inhibit the active site of mTOR in vitro, it is required for cellular activity, probably serving as an intracellular sink for RapaLink-1 to accumulate in the cell. We probed this possibility using a structural analogue of RapaLink-1, in which the TORKi moiety had been replaced with tetramethylrhodamine (RapaTAMRA; Extended Data Fig. 1). This fluorescent analogue of RapaLink-1 allowed us to quantify intracellular compound concentration by flow cytometry. Consistent with previous findings with RapaLink-1 (ref. 21) and other FKBP-binding compounds22,23, RapaTAMRA showed high cellular retention (tenfold increase in median fluorescence intensity) even after extensive washout, but this effect was diminished by knockdown of the gene encoding FKBP12 (Extended Data Fig. 1c). Although other factors may contribute, our data suggest that FKBP12-mediated cellular partitioning has a large role in the exceptional potency of RapaLink-1.

We next considered whether the dependence of RapaLink-1 on FKBP12 could be harnessed to achieve CNS-restricted mTOR inhibition. Specifically, selective blockade of FKBP12 in peripheral tissues with a potent, brain-impermeant small-molecule ligand would allow RapaLink to accumulate in the brain but not in peripheral tissues, resulting in brain-specific inhibition (Fig. 2a). To identify a candidate FKBP12 ligand with the suitable permeability profile (that is, cell permeable but blood–brain barrier (BBB) impermeable), we considered known natural and synthetic high-affinity FKBP12 ligands (for example, FK506 (refs. 24,25), rapamycin26,27 and SLF/Shield-1 (refs. 28,29)), but all of these compounds readily cross the BBB. Therefore, we synthesized a panel of derivatives of SLF and FK506 in which polar substituents (particularly hydrogen bond donors and acceptors) had been attached to the solvent-exposed parts of these two molecules, directly opposing the empirical rules for designing BBB-permeable drugs30,31 (Extended Data Fig. 2). In addition, modification of the C21 allyl of FK506 has the added advantage that it abolishes binding to calcineurin32, the natural target of FK506, whose inhibition causes suppression of nuclear factor of activated T cells (NFAT) signalling and hence immunosuppression (Fig. 2b). The majority of Shield-1 and FK506 derivatives that we synthesized maintained potent FKBP12 binding (Extended Data Fig. 2), as measured by a competition fluorescence polarization assay33. We then screened these compounds (10 µM) in a cell-based assay, evaluating whether they can protect mTOR from inhibition by RapaLink-1 (10 nM) by monitoring the level of phospho-S6 by western blot. Although some of the SLF derivatives attenuated the potency of rapamycin (rescuing phospho-S6 levels), they failed to block RapaLink-1 (Extended Data Fig. 2a). Meanwhile, most FK506 analogues were effective, with some of them completely blocking RapaLink-1 from inhibiting mTOR (Extended Data Fig. 2b). This is probably due to the lower affinity of SLF derivatives than FKBP12, consistent with our computational modelling results (see Supplementary Note 1 for details). We subjected four compounds with distinct side-chain chemotypes to an additional in vivo screen, in which mTOR signalling was separately analysed in the brain and skeletal muscle tissues of mice treated with a combination of RapaLink-1 and the candidate compound (1 and 40 mg per kg, respectively). A pyridine N-oxide derivative of FK506 (06-041) protected peripheral tissues from RapaLink-1 but allowed potent inhibition of mTOR in the brain (Extended Data Fig. 3). We therefore chose this compound for further study and refer to it as ‘RapaBlock’ (Fig. 2c).

a, Proposed model to achieve brain-specific mTOR inhibition through the combination of an FKBP12-dependent mTOR inhibitor (RapaLink-1) and a brain-impermeable FKBP12 ligand (RapaBlock). b, FK506–FKBP12 co-crystal structure (PDB: 1FKJ) showing that the C21 allyl group is solvent-exposed and its modification may lead to abolished calcineurin binding. c, Chemical structure of RapaBlock. The blue shaded area indicates the FKBP12-binding moiety. The purple portion indicates the chemical modification relative to FK506. d, Competition fluorescence polarization assay using fluorescein-labelled rapamycin as the tracer compound (n = 2; data are presented as individual points). e, Jurkat cells expressing a luciferase under the control of the NFAT transcription response element were stimulated with phorbol myristate acetate and ionomycin in the presence of various concentrations of compounds (n = 3; data are presented as mean ± s.d.).

Source data

RapaBlock and FK506 bind to FKBP12 with comparable affinity (Fig. 2d; inhibition constant (Ki): 3.1 nM and 1.7 nM, respectively), but unlike FK506, RapaBlock does not exhibit any inhibitory activity for calcineurin (Fig. 2e). In cultured cells, RapaBlock does not affect mTOR signalling by itself (up to 10 µM) but attenuates the pharmacological effects of RapaLink-1 in a dose-dependent manner (Fig. 3a). RapaBlock appears more effective at blocking rapamycin, restoring the phospho-S6 signal to the same level as untreated cells at 100:1 stoichiometry (Fig. 3d). The high affinity of RapaBlock to FKBP12 is crucial for its blocking activity—a structural analogue of RapaBlock with 100-fold reduced binding to FKBP12 failed to rescue mTOR inhibition by RapaLink-1 (Extended Data Fig. 4).

a,d, MCF7 cells were treated with a combination of RapaLink-1 and RapaBlock (a), or rapamycin and RapaBlock (d) for 4 h, then phosphorylation of mTOR substrates were analysed by immunoblotting. Results shown are representative of three independent experiments. GDPDH was used as the loading control. For gel source data, see Supplementary Fig. 1. b,e, Human PBMCs were stimulated with anti-CD3 and anti-CD28 in the presence of varying amounts of RapaLink-1 and RapaBlock (b) or rapamycin and RapaBlock (e), and cell proliferation was measured after 120 h (n = 3; data are presented as mean ± s.d.). c,f, Secretion of IL-2 in the culture supernatant of PBMCs stimulated with anti-CD3 and anti-CD28 and treated with Rapalink-1 (c) or rapamycin (f) was quantified by sandwich ELISA (n = 3; data are presented as mean ± s.d.).

Source data

Because of the important role of mTOR signalling in driving cell growth34, we asked whether RapaBlock can prevent RapaLink-1-mediated suppression of T cell proliferation in vitro. We stimulated human peripheral mononuclear blood cells (PBMCs) with anti-CD3 and anti-CD28 antibodies in the presence of different concentrations of RapaLink-1 and RapaBlock and assessed cell proliferation after 5 days. Whereas RapaLink-1 potently inhibited proliferation of PBMCs at nanomolar concentrations, addition of RapaBlock abolished this effect, shifting the IC50 by more than 100-fold (Fig. 3b). We also observed higher cumulative IL-2 release in cells co-treated with RapaLink-1 and RapaBlock than cells treated with RapaLink-1 alone (Fig. 3c). Consistent with our observation of mTOR signalling, RapaBlock appeared more effective at protecting PBMCs from rapamycin-mediated growth inhibition (Fig. 3e,f). Together, these data demonstrate that by competitively binding to intracellular FKBP12, RapaBlock renders RapaLink-1 and rapamycin incapable of inhibiting mTOR.

To examine whether the combination of RapaLink-1 and RapaBlock allows brain-specific inhibition of mTOR in vivo, we treated healthy BALB/cnu/nu mice with RapaLink-1 (1 mg per kg) or a combination of RapaLink-1 (1 mg per kg) and RapaBlock (40 mg per kg), stimulated mTOR activity with insulin (250 mU) after 4 h or 24 h, and analysed dissected tissues by immunoblot (Fig. 4a and Extended Data Fig. 5). RapaLink-1, when used as a single agent, potently inhibited mTOR signalling in both skeletal muscle and brain tissues, as revealed by the reduced phosphorylation of S6 and 4EBP1. However, the combination of RapaLink-1 and RapaBlock exhibited remarkable tissue-specific effects; although mTOR activity in the brain was inhibited at a comparable level to mice treated with RapaLink-1 only, mTOR activity in skeletal muscle was not inhibited. This tissue specificity has allowed us to inhibit mTOR activity in the mouse brain in chronic treatments without the common on-target side effects of mTOR inhibitors, such as body weight loss, impaired glucose metabolism and liver toxicity35.

a, Analysis of mTOR signalling in mouse whole brain and skeletal muscle after a single dose of RapaLink-1 (1 mg per kg), RapaBlock (40 mg per kg) or a combination of both. Quantified intensities are shown below each immunoblot as the fold increase relative to muscle or brain without insulin stimulation, normalized to GAPDH (n = 3; data are presented as mean ± s.d.). Statistical tests were performed between RapaLink-1 and RapaLink-1 + RapaBlock treatment groups at each time point (two-tailed unpaired Student’s t-test). Immunoblot images are shown for one animal from each group. See Extended Data Fig. 5 for other replicates. All samples are derived from the same experiment. Gels and blots were processed in parallel. GAPDH was the loading control. For gel source data, see Supplementary Fig. 1. b, Mice (n = 7) bearing luciferase-expressing orthotopic glioblastoma xenografts (U87MG) were treated intraperitoneally every 5 days with: (1) vehicle; (2) RapaBlock (40 mg per kg); (3) RapaLink-1 (1 mg per kg); and (4) RapaLink-1 (1 mg per kg) and RapaBlock (40 mg per kg). Tumour size and mouse weight were monitored every 5 days using bioluminescence imaging. Data are presented as mean ± s.d. Statistical tests were performed for each treatment group versus vehicle-treated group: two-tailed unpaired Student’s t-test (tumour size on day 20), and log-rank test (survival). c, Mice (n = 5) bearing luciferase-expressing orthotopic glioblastoma xenografts (GBM43) were treated intraperitoneally every 5 days with: (1) vehicle; (2) RapaBlock (60 mg per kg); (3) RapaLink-1 (1.2 mg per kg); and (4) RapaLink-1 (1.2 mg per kg) and RapaBlock (60 mg per kg). Tumour size and mouse weight were monitored every 3 days using bioluminescence imaging. Data are presented as mean ± s.d. Statistical tests were performed for each treatment group versus vehicle-treated group: two-tailed unpaired Student’s t-test (tumour size on day 10), and log-rank test (survival). NS, not significant.

Source data

RapaLink-1 has been shown to be efficacious in orthotopic mouse models of glioblastoma, but inhibition of mTOR in the periphery does not contribute to efficacy. We asked whether our combination regimen, lacking the ability to inhibit mTOR activity in peripheral tissues, could retain the efficacy of RapaLink-1 in treating glioblastoma. We established orthotopic intracranial xenografts of U87MG cells expressing firefly luciferase in nude mice and treated these mice with intraperitoneal injections of RapaLink-1 (1 mg per kg), RapaBlock (40 mg per kg) or a combination of both every 5 days. All treatments were well tolerated, and no significant changes in body weight were observed (Fig. 4b and Extended Data Fig. 6a). RapaLink-1, both as a single agent or in combination with RapaBlock, significantly suppressed tumour growth and improved survival, whereas RapaBlock alone had no significant effect on either. We next tested our treatment strategy in mice with intracranial xenografts of GBM43, a highly aggressive patient-derived glioblastoma model36. Although none of the conditions suppressed the rapid growth of the tumours, the combination of RapaLink-1 (1.2 mg per kg) and RapaBlock (60 mg per kg) conferred a survival benefit (Fig. 4c and Extended Data Fig. 6b).

Having established a binary therapeutic approach to achieve brain-specific inhibition of mTOR, we wondered whether the same strategy could be adapted to other drugs for which brain-restricted pharmacology would be desirable. One critical challenge is that for this approach to be generalizable, the ‘active’ component (for example, RapaLink-1) must be dependent on the availability of FKBP12. Drugs with this property are rare; few, if any besides rapamycin and FK506, are known. Our earlier investigation of RapaLink-1 (Fig. 1) and RapaTAMRA (Extended Data Fig. 1) led us to hypothesize that other bifunctional molecules consisting of a FKBP12-binding moiety and a kinase inhibitor moiety could be conditionally active and amenable to modulation with RapaBlock.

We first tested our hypothesis with GNE7915, a potent and specific inhibitor of leucine-rich repeat kinase 2 (LRRK2) under pre-clinical investigation for the treatment of Parkinson disease37. As gain-of-function mutations of LRRK2 are strongly associated with hereditary and sporadic forms of Parkinson disease, LRRK2 kinase inhibition has been pursued as a potential therapeutic strategy38,39. However, recent studies demonstrating that systemic LRRK2 inhibition with small-molecule inhibitors induced cytoplasmic vacuolation of type II pneumocytes have suggested a potential safety liability for these compounds40,41. We synthesized FK-GNE7915 by chemically linking the pharmacophores of FK506 and GNE7915 with a piperazine group (Fig. 5a). In in vitro LRRK2 kinase assays, FK-GNE7915 was an inferior inhibitor to GNE7915 (Fig. 5c; IC50 of 107 nM and 3.0 nM, respectively), although its activity was potentiated by including 10 µM FKBP12 in the assay (IC50 of 21 nM). However, in a cellular assay in which we quantified phospho-LRRK2 (S935) levels as a marker for LRRK2 inhibition, FK-GNE7915 was more potent than the parent compound GNE7915 by more than tenfold (Fig. 5d; IC50 of 6.7 nM and 81 nM, respectively). The juxtaposition of these two results suggested a role of the FK506 moiety in the enhanced cellular potency of FK-GNE7915. We reasoned that the high-affinity FK506–FKBP12 interaction can promote the intracellular accumulation of FK-GNE7915 similar to the case of RapaLink-1 and confirmed this using a bifunctional fluorescent probe: FK-TAMRA (Extended Data Fig. 7). This feature allowed us to programme LRRK2 inhibition by controlling the availability of FKBP12; whereas treatment with 100 nM FK-GNE7915 reduced the level of phospho-LRRK2 (S935) to 15% of the basal level, the combination of 100 nM FK-GNE7915 and 1 µM RapaBlock had no effect on LRRK2 activity (Fig. 5e).

a, Structures of GNE7915 and FK-GNE7915. b, Proposed working model for FKBP-dependent kinase inhibitors. c, Kinase inhibition in the absence or presence of supplemented 10 µM recombinant FKBP12 protein (n = 2; data are shown as individual points). d,e, RAW264.7 cells were treated with GNE7915, FK-GNE7915 and/or RapaBlock, and phospho-LRRK2 (S935) was analysed by time-resolved FRET using epitopically orthogonal antibodies for LRRK2 and p-LRRK2 (S935) (n = 3; data are presented as mean ± s.d.). See Supplementary Information for experimental details.

Source data

The successful conversion of GNE7915 into a FKBP-dependent LRRK2 inhibitor by simply linking it to an FK506 fragment prompted us to evaluate the generality of this strategy. We explored several kinase inhibitors that are being investigated for CNS diseases: dasatinib (Src family kinase inhibitor for glioblastoma)42,43, lapatinib (EGFR/HER2 inhibitor for glioblastoma)44,45 and prostetin (MAP4K4 inhibitor for amyotrophic lateral sclerosis and Alzheimer disease)46. In all three cases, chemically linking the kinase inhibitor to FK506 yielded bifunctional molecules that retained the kinase inhibitory activities of the parent molecules (Extended Data Figs. 8–10). For FK-dasatinib, we also examined its target specificity using both biochemical (Invitrogen SelectScreen Kinase Profiling; Supplementary Table 1) and live-cell kinase profiling47. Among the reported targets of dasatinib, Src family kinases were potently inhibited by both dasatinib and FK-dasatinib, whereas a few tyrosine kinases (for example, DDR2) exhibited differential susceptibility to these two inhibitors (Extended Data Fig. 8c). Despite their large molecular weights, these bifunctional molecules were active in cells with comparable potencies to their parent compounds and sensitive to deactivation by RapaBlock. Although these examples represent a limited set of kinase inhibitors with potential CNS disease indications, it is conceivable that more drugs can be similarly configured with programmable pharmacology without losing cellular potency.

By exploiting the unique functional dependence of rapamycin analogues on FKBP12, we have developed an approach to achieve brain-specific mTOR inhibition through the simultaneous administration of a potent mTOR inhibitor (RapaLink-1) and a cell-permeable, BBB-impermeable ligand of FKBP12 (RapaBlock). Tissue-restricted mTOR inhibition enabled by this binary pharmacology strategy reduced the toxicity in peripheral tissues but maintained therapeutic benefits of RapaLink-1 in glioblastoma xenograft models. On the basis of these findings, it seems reasonable to anticipate that the same drug combination may be of broader value in other CNS diseases driven by dysregulated mTOR activity such as alcohol use disorder35.

The applicability of our approach extends beyond mTOR inhibition. We show that chemically linking ATP-site kinase inhibitors to FK506 through solvent-exposed groups leads to a new class of cell-permeable kinase inhibitors whose activity depends on the abundant endogenous protein FKBP12. These inhibitors are characterized by their ability to mediate the formation of a ternary complex of the drug, the target kinase and FKBP12, as well as their amenability to activity modulation by RapaBlock. Further in vivo studies and medicinal chemistry are necessary to assess and optimize these compounds on a case-by-case basis, but our initial investigations show that it is feasible to attain brain-selective kinase inhibition of LRRK2 using a FKBP-dependent kinase inhibitor (FK-GNE7915) and RapaBlock.

We have investigated the mechanism by which RapaBlock controls the cellular activity of RapaLink-1 as well as other FKBP12-dependent kinase inhibitors. Our current data have revealed at least two roles of cellular FKBP12 in the function of RapaLink-1 (and other FKBP12-binding compounds). First, we have shown that FKBP12 serves as a reservoir to retain and accumulate RapaLink-1 inside the cell, achieving exceptional cellular concentration. Second, for most FKBP12-dependent kinase inhibitors that we have investigated, FKBP12 improves their potency in cell-free assays. Although we have not obtained direct evidence, we hypothesize that in aqueous solutions, a bifunctional compound built with flexible linkers between hydrophobic pharmacophores will mainly adopt a binding-incompetent conformation to minimize hydration penalty (‘hydrophobic collapse’), and binding of FKBP12 will expose the inhibitor moiety to enable target inhibition. RapaBlock impedes both of these processes by occupying the ligand-binding site of FKBP12. Although further investigation is clearly necessary to elucidate how these high-molecular-weight compounds enter cells and whether FKBP12 participates in the binding interaction with the target protein, we believe that this system provides a generalizable approach for programmable kinase inhibition.

Combining two pharmaceutical agents to achieve tissue-selective therapeutic effects has been previously used in drugs approved for clinical use or in development. Examples include levodopa–carbidopa (BBB-permeable dopamine precursor–BBB-impermeable DOPA decarboxylase inhibitor) for Parkinson disease48, conjugated oestrogens–bazedoxifene (BBB-permeable oestrogen–BBB-impermeable oestrogen receptor modulator) for post-menopausal hot flashes and osteoporosis49, and donepezil–solifenacin (BBB-permeable acetylcholinesterase inhibitor–BBB-impermeable anticholinergic) for Alzheimer disease50. Our approach differs from these precedents in that it does not involve two drugs with counteracting effects on the same target or pathway; instead, RapaBlock controls tissue specificity by directly attenuating the activity of the kinase inhibitor. The present system therefore has the advantage of being adaptable for a multitude of targets, only requiring an invariant RapaBlock molecule and a FKBP12-dependent inhibitor that can be readily designed based on the structures of FK506 and lead compounds. Although we have focused on protein kinases in this study, it seems reasonable to expect that the approach is also applicable to other classes of therapeutic targets, such as GTPases and histone modification enzymes.

DNA sequences encoding full-length human FKBP12 were synthesized by Twist Biosciences and cloned into the pET47b vector using standard molecular biology techniques. Protein expression was performed in BL21(DE3) Escherichia coli strain. In brief, chemically competent BL21(DE3) cells were transformed with pET47b-FKBP12 and grown on LB medium plates containing 50 µg ml–1 kanamycin at 37 °C. A single colony was used to inoculate a culture at 37 °C at 220 r.p.m. in terrific broth containing 50 µg ml–1 kanamycin. When the optical density reached 0.6, protein expression was induced by the addition of IPTG to 1 mM. After 2 h at 37 °C, the cells were pelleted by centrifugation (6,500g for 10 min) and lysed in lysis buffer (20 mM Tris 8.0, 500 mM NaCl and 5 mM imidazole) with a high-pressure homogenizer (Microfluidics). The lysate was clarified by high-speed centrifugation (19,000g for 15 min) and the supernatant was used in subsequent purification by immobilized metal affinity chromatography. His-tagged FKBP12 was captured by incubation with Co-TALON resin (Clonetech, Takara Bio USA, 4 ml slurry per litre culture) at 4 °C for 1 h with constant end-to-end mixing. The loaded beads were then washed with lysis buffer (50 ml l–1 culture) and the protein was eluted with elution buffer (20 mM Tris 8.0, 500 mM NaCl and 300 mM imidazole). The His-tag was cleaved with His-tagged HRV 3C Protease (Clonetech, Takara Bio USA, 5 U l–1 culture) at 4 °C until liquid chromatography–mass spectrometry analysis of the reaction mixture indicated more than 95% cleavage. The reaction mixture was concentrated using a 10K MWCO centrifugal concentrator (Amicon-15, Millipore) to 20 mg ml–1 and purified by size-exclusion chromatography on a Superdex 75 10/300 GL column (GE Healthcare Life Sciences) with SEC buffer (20 mM HEPES pH 7.5 and 150 mM NaCl). Fractions containing pure FKBP12 protein were pooled and concentrated to 20 mg ml–1 and stored at –78 °C. This protocol gives a typical yield of 10–20 mg l–1 culture for FKBP12.

Compound binding affinity was determined using a competition fluorescence polarization assay. A fluorescent tracer molecule based on rapamycin (FITC-Rapa)33 was synthesized in house. The assay buffer was 20 mM HEPES pH 7.5 and 0.01% Triton X-100. The dissociation constant (Kd) of the tracer molecule for FKBP12 was first determined by measuring fluorescence polarization (excitation of 485 nm and emission of 535 nm) at various protein concentrations and fitting the curve to a quadratic binding model. To measure compound binding affinity, mixtures with the following composition were prepared in duplicate in 96-well black opaque plates (Corning 3915): 0.5 nM FITC-Rapa, 1 nM FKBP12, 5% DMSO and 5 µM to 0.08 nM of test compound, 200 µl total volume. Fluorescence polarization was measured on a TECAN Spark 20M plate reader (excitation of 485 nm and emission of 535 nm). Data were fitted to a three-parameter sigmoidal curve to derive IC50 values. Ki of the compounds were calculated using a tool provided by S. Wang’s laboratory (http://www.umich.edu/~shaomengwanglab/software/calc_ki/index.html). Data were plotted in GraphPad Prism 9.0.

MCF7 cells were obtained from the American Type Culture Collection (ATCC; HTB-22) and maintained in 1:1 DMEM:F12 (Gibco) plus 10% heat-inactivated FBS (Axenia Biologix) supplemented with 4 mM l-glutamine, 100 U ml–1 penicillin and 100 U ml–1 streptomycin (Gibco). SK-BR-3 cells were obtained from the ATCC (HTB-30) and maintained in McCoy’s 5A (Gibco) plus 10% heat-inactivated FBS supplemented with 2 mM l-glutamine, 100 U ml–1 penicillin and 100 U ml–1 streptomycin (Gibco). K562 CRISPRi cells were a gift from L. Gilbert and maintained in RPMI 1640 (Gibco) plus 10% heat-inactivated FBS supplemented with 2 mM l-glutamine, 100 U ml–1 penicillin, 100 U ml–1 streptomycin (Gibco) and 0.1% Pluronic F-68 (Gibco). RAW264.7 cells were obtained from the ATCC (TIB-71) and maintained in DMEM (Gibco) plus 10% heat-inactivated FBS supplemented with 2 mM l-glutamine, 100 U ml–1 penicillin and 100 U ml–1 streptomycin (Gibco). Jurkat cells were obtained from the ATCC (TIB-152) and maintained in RPMI 1640 (Gibco) plus 10% heat-inactivated FBS supplemented with 2 mM l-glutamine, 100 U ml–1 penicillin and 100 U ml–1 streptomycin (Gibco). Jurkat-Lucia NFAT cells were obtained from InvivoGen and maintained in IMDM (Gibco) plus 10% heat-inactivated FBS supplemented with 2 mM l-glutamine, 100 U ml–1 penicillin, 100 U ml–1 streptomycin (Gibco) and 100 µg ml–1 Zeocin (InvivoGen). HEK293T cells were obtained from UCSF Cell Culture Facility and maintained in 1:1 DMEM:F12 (Gibco) plus 10% heat-inactivated FBS supplemented with 4 mM l-glutamine, 100 U ml–1 penicillin and 100 U ml–1 streptomycin (Gibco). All cell lines tested mycoplasma negative using the MycoAlert Mycoplasma Detection Kit (Lonza). Cell lines from the ATCC were short randem repeat (STR) profiled by the manufacturer. Jurkat-Lucia NFAT cells are a commercial cell line developed by InvivoGen and was authenticated by the manufacturer. Cell lines from UCSF Cell Culture Facility were STR profiled by the UCSF Cell Culture Facility. No further authentications were performed after the purchase. When indicated, cells were treated with drugs at 60–80% confluency at a final DMSO concentration of 1%. At the end of the treatment period, cells were placed on ice and washed once with PBS. Unless otherwise indicated, the cells were scraped with a spatula, pelleted by centrifugation (500g for 5 min) and lysed in RIPA buffer (25 mM Tris pH 7.4, 150 mM NaCl, 0.1% SDS 1% NP-40 and 0.5% sodium deoxycholate) supplemented with protease and phosphatase inhibitors (cOmplete and phosSTOP, Roche) on ice for 10 min. Lysates were clarified by high-speed centrifugation (19,000g for 10 min). Concentrations of lysates were determined with a protein BCA assay (Thermo Fisher) and adjusted to 2 mg ml–1 with additional RIPA buffer. Samples were mixed with 5× SDS loading dye and heated at 95 °C for 5 min.

Unless otherwise noted, SDS–PAGE was run with Novex 4–12% Bis-Tris gel (Invitrogen) in MES running buffer (Invitrogen) at 200 V for 40 min following the manufacturer’s instructions. Protein bands were transferred onto 0.45-µm nitrocellulose membranes (Bio-Rad) using a wet-tank transfer apparatus (Bio-Rad Criterion Blotter) in 1× TOWBIN buffer with 10% methanol at 75 V for 45 min. Membranes were blocked in 5% BSA–TBST for 1 h at 23 °C. Primary antibody binding was performed with the indicated antibodies diluted in 5% BSA–TBST at 4 °C for at least 16 h. After washing the membrane three times with TBST (5 min for each wash), secondary antibodies (goat anti-rabbit IgG-IRDye 800 and goat anti-mouse IgG-IRDye 680; Li-COR) were added as solutions in 5% skim milk–TBST at the dilutions recommended by the manufacturer. Secondary antibody binding was allowed to proceed for 1 h at 23 °C. The membrane was washed three times with TBST (5 min for each wash) and imaged on a Li-COR Odyssey fluorescence imager. See Supplementary Table 2 for a full list of antibodies used in this study.

Jurkat-Lucia NFAT cells were resuspended to 2 × 106 cells per ml in fresh growth medium and dispensed in 96-well tissue culture plates (Corning 3904; 180 µl per well). DMSO solutions of test compounds at 100× the test concentrations were added and the cells were incubated for 4 h at 37 °C. A 10× stimulation solution containing phorbol myristate acetate (100 ng ml–1) and ionomycin (10 µg ml–1) were added to each well (20 µl per well) except for the negative control wells, which were supplemented with 20 µl medium. Cells were incubated at 37 °C for 12 h. Cells (20 µl per well) were transferred into a white opaque 96-well plate (Corning 3912). TECAN Spark 20M plate reader equipped with an auto-injection system was primed with Lucia luciferase substrate solution and set with the following parameters: 50 µl of injection volume, end-point measurement with a 4-s delay time and 0.1-s integration time. Luciferase activity was measured with the settings above and normalized to DMSO-treated, stimulated cells. Data were plotted in GraphPad Prism 9.0.

Jurkat cells were cultured and treated as described in the ‘Cell culture’ section. At the end of treatment period, 1.5 ml aliquot of cells were pelleted (500g for 5 min) and washed once with serum-free RPMI (1 ml). The supernatant was removed, and the cells were resuspended in 100 µl 5 µg ml–1 OKT3 (Invitrogen; functional grade) in RPMI and immediately placed in a 37 °C water bath. At 5 min, 25 µl 5× SDS loading buffer was added and mixed quickly with the cells. The sample was sonicated at 30% power output for 60 s (1 s on, 1 s off) using Qsonica Q500 Sonicator to shear the DNA. The samples were heated at 95 °C for 5 min and used for SDS–PAGE.

Phospho-LRRK2 (S935) was quantified in drug-treated cells using a Phospho-LRRK2 (Ser935) cellular kit (Cisbio) following the manufacturer’s instructions. RAW264.7 (2 × 105 cells per ml) cells were plated in six-well tissue culture plates (2 ml per well) 24 h before treatment. Cells were treated with compounds at the indicated concentrations for 2 h. Medium was removed by aspiration and the cells were rinsed with ice-cold PBS (1 ml). Cells were lysed with 100 µl Cisbio 1X lysis buffer at 23 °C directly in plate for 30 min. The lysates were transferred into microcentrifuge tubes and clarified by centrifugation (19,000g for 10 min). Clarified lysate (16 µl) was dispensed into one well of a low-volume, round-bottom 384-well plate, and 4 µl LRRK2–phospho-LRRK2 (S935) antibody master mix (Cisbio) was added to each well. The plate was incubated at 23 °C for 4 h. Time-resolved fluorescence was read on a TECAN Spark 20M plate reader with the following parameters: lag time of 60 µs; integration time of 500 µs; read A included excitation filter of 320 (25) nm, emission filter of 610 (25) nm and gain of 130; read B included excitation filter of 320 (25) nm, emission filter of 665 (8) nm and gain of 165.

The TR-FRET signal was calculated as the ratio fluorescence intensity [read B]/[read A]. Data were plotted in GraphPad Prism 9.0.

HEK293T cells were transfected with standard packaging vectors using the TransIT-LT1 Transfection Reagent (Mirus Bio). Viral supernatant was collected 2–3 days after transfection, filtered through 0.45-μm polyvinylidene difluoride filters (Millipore Sigma) and frozen at –80 °C before transduction.

sgRNA protospacers targeting GAL4-4 (negative control sg GAACGACTAGTTAGGCGTGTA) and FKBP12 (FKBP12 sg1 GACGGCTCTGCCTAGTACCT and FKBP12 sg2 GCCCAGGAGACGGTGAGTAG)51 were cloned into pCRISPRia-v2 (marked with a puromycin resistance cassette and BFP; Addgene #84832). In brief, complementary synthetic oligonucleotides (Integrated DNA Technologies) with flanking BstXI and BlpI restriction sites were annealed and ligated with BstXI- and BlpI-digested pCRISPRia-v2. The sgRNA expression vectors were packaged into lentivirus as described above. Knockdown cells were generated by transducing K562 CRISPRi (sgRNA–) cells with the sgRNA expression vectors at a multiplicity of infection of less than 1 (20–40% transduction rate) with 8 μg ml–1 polybrene. Beginning the second day following lentiviral addition, transduced (sgRNA+) cells were selected using 2 μg ml–1 puromycin (Gibco) until each cell population stably reached 95% or more BFP+ (405-nm excitation laser, and 440/50-nm emission filter) by flow cytometry on an Attune NxT (Thermo Fisher Scientific).

Cells were seeded into 96-well white flat bottom plates (1,000 cells per well) (Corning) and incubated overnight. Cells were treated with the indicated compounds in a nine-point threefold dilution series (100 μl final volume) and incubated for 72 h. In some conditions, 10 μM FK506 was uniformly added to the dilution series. Cell viability was assessed using a commercial CellTiter-Glo (CTG) luminescence-based assay (Promega). In brief, the 96-well plates were equilibrated to room temperature before the addition of diluted CTG reagent (100 μl) (1:4 CTG reagent:PBS). Plates were placed on an orbital shaker for 30 min before recording luminescence using a Spark 20M (TECAN) plate reader. Data were plotted in GraphPad Prism 9.0.

Untransduced (no virus or sgRNA–) and sgRNA expression vector-transduced (sgRNA+) K562 CRISPRi cells were mixed in a 1:1 ratio, plated in 48-well plates and incubated overnight. Cell mixtures were treated with the indicated TAMRA-linked compounds (300 μl final volume) and incubated for 24 h. Plates were placed over ice and 200 μl of each compound–cell mixture was transferred to a 96-well U-bottom plate. Cells were pelleted at 500g for 5 min and subsequently washed 2× with ice-cold FACS buffer (PBS + 1% BSA + 0.1% NaN3). Cells were resuspended in 200 μl of ice-cold FACS buffer and assessed using an Attune NxT (Thermo Fisher Scientific). Relative uptake of TAMRA-linked compounds was determined by comparing TAMRA fluorescence (561-nm excitation laser and 585/16-nm emission filter) between sgRNA– and sgRNA+ cells within each well.

In vitro kinase inhibition assays were performed by SelectScreen Services (Thermo Fisher Scientific) using either Z’-LYTE (mTOR, Src, Csk, EGFR, HER2 and HGK), Adapta (LRRK2) or LanthaScreen (DDR2) assay format (standardized protocols can be accessed on the SelectScreen website: https://www.thermofisher.com/us/en/home/products-and-services/services/custom-services/screening-and-profiling-services/selectscreen-profiling-service/selectscreen-kinase-profiling-service.html. When indicated, recombinant FKBP12 protein was added to the assay mixture to a final concentration of 10 µM.

All animal experiments were conducted using protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, San Francisco. Female athymic BALB/Cnu/nu athymic nude mice (4–6 weeks old) were used for in vivo experiments. All mice at the Helen Diller Cancer Center UCSF were housed in individually ventilated microisolator cages. The housing racks had automatic water that was sterilized through filtration, reverse osmosis and UV light exposure. All mice were fed a standard diet that was pre-irradiated. The light–dark cycle was 12 h light–12 h dark. Temperature was maintained in the range of 68–74 °F. Humidity was maintained at 30–70%. Western blot analysis of mTOR signalling used 4–6-week-old female athymic BALB/Cnu/nu mice (three per group; randomized) that were treated with intraperitoneal injections of vehicle (20% DMSO, 40% PEG-300 and 40% PBS (v/v)), RapaLink-1 (1 mg per kg), RapaBlock (40 mg per kg), and a combination of RapaLink-1 (1 mg per kg) and RapaBlock (40 mg per kg) for 15 min, followed by intraperitoneal injection of 250 mU insulin or saline, then euthanized 15 min later. Skeletal muscle and brain from each mouse were lysed and analysed by western blotting. For orthotopic injections and treatment studies, female BALB/Cnu/nu mice (4–6 weeks old) were anaesthetized using isoflurane. U87MG cells (3 × 105) expressing firefly luciferase were injected intracranially (Hamilton syringe) at coordinates 2 mm anterior and 1.5 mm lateral of the right hemisphere relative to Bregma, at a depth of 3 mm. Whole-brain bioluminescence was measured for each mouse every 5 days. When bioluminescence reached 106 photons per second, mice were randomized to four groups of equal mean bioluminescent signal (seven mice per group) and therapy was initiated. Groups were treated with intraperitoneal injection of vehicle (20% DMSO, 40% PEG-300 and 40% PBS (v/v)), RapaLink-1 (1.0 mg per kg), RapaBlock (40 mg per kg), or a combination of RapaLink-1 (1.0 mg per kg) and RapaBlock (40 mg per kg) every 5 days for 25–30 days. Mice were monitored daily and euthanized when they exhibited neurological deficits or 15% reduction from initial body weight. For GBM43 xenograft studies, GBM43 cells (1 × 105) expressing firefly luciferase were injected intracranially (Hamilton syringe) at coordinates 2 mm anterior and 1.5 mm lateral of the right hemisphere relative to Bregma, at a depth of 3 mm. Whole-brain bioluminescence was measured for each mouse every 5 days. When bioluminescence reached 106 photons per seconds, mice were randomized to four groups of equal mean bioluminescent signal (five mice per group), and therapy was initiated. Groups were treated with intraperitoneal injection of vehicle (20% DMSO, 40% PEG-300 and 40% PBS (v/v)), RapaLink-1 (1.2 mg per kg), RapaBlock (60 mg per kg), or a combination of RapaLink-1 (1.2 mg per kg) and RapaBlock (60 mg per kg) every 5 days for 15–20 days. Mice were monitored daily and euthanized when they exhibited neurological deficits or 15% reduction from initial body weight. Researchers were blinded from mice group assignment for imaging luciferase activity and measuring tumour burden.

See Supplementary Notes 2 and 3 for details on chemical synthesis and 1H and 13C NMR spectra of RapaBlock.

Further information on research design is available in the Nature Research Reporting Summarylinked to this article.

Unprocessed gel images for all immunoblots (Figs. 1d, 3a,d and 4a and Extended Data Figs. 3, 4c, 5, 8e,f and 9d) are provided in Supplementary Fig. 1. Raw data for the kinase inhibition assays, cell growth assays and xenograft studies are available as source data files. All data that support the findings of this study are available from the corresponding author on reasonable request. Source data are provided with this paper.

Johnson, T. E. et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol. Appl. Pharmacol. 200, 237–250 (2004).

CAS PubMed Google Scholar

Reiner, P. B. & Kamondi, A. Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current. Neuroscience 59, 579–588 (1994).

CAS PubMed Google Scholar

Li, M. et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J. Rare Dis. 14, 1–9 (2019).

Google Scholar

Franz, D. N. et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490–498 (2006).

CAS PubMed Google Scholar

Rageot, D. et al. Discovery and preclinical characterization of 5-[4,6-bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders. J. Med. Chem. 61, 10084–10105 (2018).

CAS PubMed Google Scholar

Akhavan, D., Cloughesy, T. F. & Mischel, P. S. Learned from bench to bedside. Neuro Oncol. 12, 882–889 (2010).

CAS PubMed PubMed Central Google Scholar

Fan, Q. W. et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell 31, 424–435 (2017).

CAS PubMed PubMed Central Google Scholar

Lapointe, S. et al. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Invest. New Drugs 38, 1137–1144 (2020).

CAS PubMed Google Scholar

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04774952 (2022).

Neasta, J. et al. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proc. Natl Acad. Sci. USA 107, 20093–20098 (2010).

ADS CAS PubMed PubMed Central Google Scholar

Barak, S. et al. Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse. Nat. Neurosci. 16, 1111–1117 (2013).

CAS PubMed PubMed Central Google Scholar

Morisot, N., Novotny, C. J., Shokat, K. M. & Ron, D. A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice. Addict. Biol. 23, 713–722 (2018).

CAS PubMed Google Scholar

Pallet, N. & Legendre, C. Adverse events associated with mTOR inhibitors. Expert Opin. Drug Saf. 12, 177–186 (2013).

CAS PubMed Google Scholar

González, D. et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr. Nephrol. 26, 961–966 (2011).

PubMed Google Scholar

Chiu, M. I., Katz, H. & Berlin, V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl Acad. Sci. USA 91, 12574–12578 (1994).

ADS CAS PubMed PubMed Central Google Scholar

Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457–468 (2002).

CAS PubMed Google Scholar

Gaubitz, C. et al. Molecular basis of the rapamycin insensitivity of target of rapamycin complex 2. Mol. Cell 58, 977–988 (2015).

CAS PubMed Google Scholar

Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, 0371-0383 (2009).

Google Scholar

García-Martínez, J. M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).

PubMed Google Scholar

Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032 (2009).

CAS PubMed PubMed Central Google Scholar

Rodrik-Outmezguine, V. S. et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534, 272–276 (2016).

ADS CAS PubMed PubMed Central Google Scholar

Marinec, P. S. et al. FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. Proc. Natl Acad. Sci. USA 106, 1336–1341 (2009).

ADS CAS PubMed PubMed Central Google Scholar

Orange, D. E. et al. Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo. eLife 2, e00105 (2013).

PubMed PubMed Central Google Scholar

Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807–815 (1991).

CAS PubMed Google Scholar

Griffith, J. P. et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82, 507–522 (1995).

CAS PubMed Google Scholar

Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756–758 (1994).

ADS CAS PubMed Google Scholar

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35–43 (1994).

CAS PubMed Google Scholar

Holt, D. A. et al. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands. J. Am. Chem. Soc. 115, 9925–9938 (1993).

CAS Google Scholar

Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G. & Wandless, T. J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995–1004 (2006).

CAS PubMed PubMed Central Google Scholar

Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541–553 (2005).

PubMed PubMed Central Google Scholar

Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem. 58, 2584–2608 (2015).

CAS PubMed Google Scholar

Clemons, P. A. et al. Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors. Chem. Biol. 9, 49–61 (2002).

CAS PubMed Google Scholar

Kozany, C., März, A., Kress, C. & Hausch, F. Fluorescent probes to characterise FK506-binding proteins. ChemBioChem 10, 1402–1410 (2009).

CAS PubMed Google Scholar

Dumont, F. J., Staruch, M. J., Koprak, S. L., Melino, M. R. & Sigal, N. H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144, 251–258 (1990).

CAS PubMed Google Scholar

Ehinger, Y. et al. Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice. Nat. Commun. 12, 4407 (2021).

ADS CAS PubMed PubMed Central Google Scholar

Sarkaria, J. N. et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12, 2264–2271 (2006).

CAS PubMed Google Scholar

Estrada, A. A. et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 57, 921–936 (2014).

CAS PubMed Google Scholar

Lee, B. D., Dawson, V. L. & Dawson, T. M. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson’s disease. Trends Pharmacol. Sci. 33, 365–373 (2012).

CAS PubMed PubMed Central Google Scholar

Rudenko, I. N., Chia, R. & Cookson, M. R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson’s disease? BMC Med. 10, 20 (2012).

CAS PubMed PubMed Central Google Scholar

Fuji, R. N. et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med. 7, 273ra15 (2015).

PubMed Google Scholar

Baptista, M. A. S. et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci. Transl. Med. 12, eaav0820 (2020).

CAS PubMed Google Scholar

Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004).

CAS PubMed Google Scholar

Lassman, A. B. et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 17, 992–998 (2015).

CAS PubMed PubMed Central Google Scholar

Medina, P. J. & Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30, 1426–1447 (2008).

CAS PubMed Google Scholar

Thiessen, B. et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 65, 353–361 (2010).

CAS PubMed Google Scholar

Bos, P. H. et al. Development of MAP4 kinase inhibitors as motor neuron-protecting agents. Cell Chem. Biol. 26, 1703–1715.e37 (2019).

CAS PubMed PubMed Central Google Scholar

Zhao, Q. et al. Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes. J. Am. Chem. Soc. 139, 680–685 (2017).

CAS PubMed PubMed Central Google Scholar

Bartholini, G., Burkard, W. P., Pletscher, A. & Bates, H. M. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215, 852–853 (1967).

ADS CAS PubMed Google Scholar

Komm, B. S. & Mirkin, S. Evolution of the tissue selective estrogen complex (TSEC). J. Cell. Physiol. 228, 1423–1427 (2013).

CAS PubMed Google Scholar

Chase, T. N., Farlow, M. R. & Clarence-Smith, K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer’s disease. Neurotherapeutics 14, 405–416 (2017).

CAS PubMed PubMed Central Google Scholar

Horlbeck, M. A. et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife 5, e19760 (2016).

Article CAS PubMed PubMed Central Google Scholar

Download references

We thank J. Koach for help with data processing; D. Wassarman for discussions; our UCSF colleague M. Evans and his group for many discussions and mouse brain imaging studies; and L. Gilbert for the generous gift of K562 CRISPRi (dCas9-KRAB) cells. Z.Z. is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-2281-17). K.L. acknowledges NIH F30CA239476. K.M.S., Q.F. and W.A.W. acknowledge NIH 1R01CA221969. K.M.S. and W.A.W. acknowledge the Samuel Waxman Cancer Research Foundation. W.A.W. acknowledges NIH U01CA217864 and Cancer Research UK A28592. K.M.S. acknowledges the Michael J. Fox Foundation P0536220, The Mark Foundation for Cancer Research and the Howard Hughes Medical Institute.

Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, CA, USA

Ziyang Zhang, Kevin Lou & Kevan M. Shokat

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Qiwen Fan, Xujun Luo & William A. Weiss

Department of Neurology, University of California, San Francisco, CA, USA

Qiwen Fan, Xujun Luo & William A. Weiss

Department of Pediatrics, University of California, San Francisco, CA, USA

William A. Weiss

Department of Neurological Surgery, University of California, San Francisco, CA, USA

William A. Weiss

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

Z.Z., Q.F., W.A.W. and K.M.S. conceived the project, designed and analysed the experiments, and wrote the manuscript. W.A.W. supervised the in vivo experiments. Z.Z. performed chemical synthesis, the biochemical assays and cell culture experiments, and analysed the data. K.L. performed the flow cytometry experiments and growth inhibition assays in K562 CRISPRi cell lines and analysed the data. Q.F. and X.L. performed the in vivo experiments and immunoblot analysis of the tissue samples, and analysed the data.

Correspondence to Kevan M. Shokat.

Z.Z., Q.F., W.A.W. and K.M.S. are co-inventors on patent applications covering RapaBlock owned by UCSF. K.M.S. is an inventor on patents covering RapaLink-1 owned by UCSF and licensed to Revolution Medicines. K.M.S. receives monetary and stock compensation and is an SAB member of Genentech/Roche, Denali Therapeutics and Revolution Medicines. Kin of K.L. hold stock in and are employed by Pharmaron.

Nature thanks Nathanael Gray, Ingo Mellinghoff and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

a, Illustration of the flow cytometry-based assay to assess cellular accumulation of TAMRA compounds. b, Structure of a fluorescent probe RapaTAMRA. c, FKBP12 knockdown decreases cellular retention of RapaTAMRA, but not TAMRA-PEG8-N3. Flow cytometry scatter plots shown are representative of three independent replicates, which are summarized in the bar graphs. Data are presented as mean values +/− SD with individual data points. Fold change is calculated as the ratio between means (sgRNA+/sgRNA−). See Supplementary Fig. 2 for gating strategy.

(a, SLF derivatives; b, FK506 derivatives). Listed in the table are their affinity to recombinant FKBP12 (fluorescence polarization assay) and their efficacy of blocking mTOR inhibition by rapamycin or RapaLink-1 (assessed by western blot analysis of p-S6 level after treatment of MCF7 cells with a combination of 10 nM Rapamycin/Rapalink + 10 µM candidate compound for 24 h. P-S6 level is quantified as fraction of DMSO control). ND, not determined. Calculated logP (cLogP) and topological polar surface area (tPSA) values were calculated using PerkinElmer ChemDraw 16.0. Hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) numbers were determined at pH 7.4 using ChemAxon Marvin Sketch 20.21. Compound 06–039 is identical to compound 05–084 but prepared in a separate batch. Compound 06–041 is identical to compound 05–086 but prepared in a separate batch.

GAPDH is a loading control. Data in (a) is representative of two independent experiments. Data in (b) is from one experiment with n = 2 for each treatment condition. For gel source data, see Supplementary Fig. 1.

a) Structures of RapaBlock and RapaBlock ethyl oxime. b) RapaBlock ethyl oxime shows attenuated affinity to FKBP12 (n = 3, data are presented as mean values +/− SD). c) RapaBlock ethyl oxime is less potent at blocking RapaLink-1. Data is representative of two independent experiments. For gel source data, see Supplementary Fig. 1.

Mice were treated intraperitoneally with a single dose of RapaLink-1 (1 mg/kg), RapaBlock (40 mg/kg), or a combination of both. mTOR activity was stimulated with insulin (250 mU) 15 min before tissue dissection. Whole brain and skeletal muscle were analyzed by immunoblot. The intensities of p-RPS6 and p-4EBP1 were quantified by densitometry using Silver Fast Scanner and ImageJ software and shown below each immunoblot as fold increase relative to muscle or brain without insulin stimulation, normalized to GAPDH. For gel source data, see Supplementary Fig. 1.

a, U87MG cells expressing firefly luciferase were injected intracranially into BALB/cnu/nu mice. After tumor establishment, mice were sorted into four groups and treated by i.p. injections every 5 days of vehicle, RapaLink-1 (1 mg/kg), RapaBlock (40 mg/kg), or a combination of RapaLink-1 and RapaBlock (1 mg/kg and 40 mg/kg, respectively). Bioluminescence imaging of tumor-bearing mice was obtained at days shown (day 0 was start of treatment), using identical imaging conditions. b, GBM43 cells expressing firefly luciferase were injected intracranially into BALB/cnu/nu mice. After tumor establishment, mice were sorted into four groups and treated by i.p. injections every 5 days of vehicle, RapaLink-1 (1.2 mg/kg), RapaBlock (60 mg/kg), or a combination of RapaLink-1 and RapaBlock (1.2 mg/kg and 60 mg/kg, respectively). Bioluminescence imaging of tumor-bearing mice was obtained at days shown (day 0 was start of treatment), using identical imaging conditions.

a, Structure of a fluorescent probe FK-TAMRA. b, FKBP12 knockdown decreases cellular retention of FK-TAMRA. Flow cytometry scatter plots shown are representative of three independent replicates, which are summarized in the bar graphs. Data are presented as mean values +/− SD with individual data points. Fold change is calculated as the ratio between means (sgRNA+/sgRNA−). See Supplementary Fig. 2 for gating strategy.

a, Structures of Dasatinib and FK-Dasatinib. b, Proposed working model for FKBP-dependent kinase inhibitors. c, Inhibition of Src, Csk and DDR2 kinases by Dasatinib and FK-Dasatinib in the absence or presence of supplemented 10 µM recombinant FKBP12 protein (n = 2, data are presented as individual points). d, Inhibition of K562 cell proliferation by Dasatinib and FK-Dasatinib, in the presence or absence of 10 µM RapaBlock (n = 3, data are presented as mean values +/− SD). e, Jurkat cells were stimulated with anti-CD3 antibody (OKT3) in the presence of dasatinib, FK-dasatinib, and/or RapaBlock and analyzed by immunoblot. COX IV is a loading control. Data is representative of two independent experiments. f, Jurkat cells were pulse-treated with Dasatinib (100 nM) or FK-Dasatinib (100 nM) for 1 h, then drugs were washed out and cells were incubated in drug-free media for various amounts of time, stimulated with anti-CD3 antibody (OKT3) for 5 min and analyzed by immunoblot. Results shown are representative of three independent experiments. COX-IV is a loading control. For gel source data, see Supplementary Fig. 1. g, inhibition of 476 purified kinases by Dasatinib (10 nM) or FK-Dasatinib (10 nM) in the presence of 10 µM recombinant FKBP12 protein (n = 1). See Supplementary Table 1 for a full list of kinase inhibition data. h, kinase profiling of Dasatinib (100 nM Dasatinib) or FK-Dasatinib (100 nM) in Jurkat cells using the covalent occupancy probe XO44. Results shown are representative of two independent experiments.

a, Chemical structures of Lapatinib and FK-Lapatinib. b, Inhibition of EGFR and HER2 kinase activity by Lapatinib and FK-Lapatinib in the absence or presence of supplemented 10 µM recombinant FKBP12 protein (n = 2, data are presented as individual points). c, Inhibition of proliferation of SK-BR3 cells by lapatinib and FK-lapatinib in the presence of absence of 10 µM RapaBlock (n = 3, data are presented as mean values +/− SD). d, SK-BR3 cells were treated with Lapatinib, FK-Lapatinib, and/or RapaBlock for 1 h and analyzed by immunoblot. Results shown are representative of three independent experiments. GAPDH is a sample processing control. For gel source data, see Supplementary Fig. 1.

a, Chemical structures of Prostetin and FK-Prostetin. b, Inhibition of MAP4K4(HGK) kinase activity by Lapatinib and FK-Lapatinib in the absence or presence of supplemented 10 µM recombinant FKBP12 protein (n = 2, data are presented as individual points).

This file contains Supplementary Figs. 1 and 2, Supplementary Table 2 (Supplementary Table 1 supplied separately) and Supplementary Notes 1–3 – see contents page for details.

Kinase profiling results of FK-dasatinib.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Zhang, Z., Fan, Q., Luo, X. et al. Brain-restricted mTOR inhibition with binary pharmacology. Nature 609, 822–828 (2022). https://doi.org/10.1038/s41586-022-05213-y

Download citation

Received: 13 October 2020

Accepted: 09 August 2022

Published: 14 September 2022

Issue Date: 22 September 2022

DOI: https://doi.org/10.1038/s41586-022-05213-y

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Molecular Cancer (2023)

Nature (2022)

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.